Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone ElseInvestors Business Daily • 12/18/24
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030The Motley Fool • 12/16/24
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall StreetThe Motley Fool • 12/15/24
Viking Stock Pops, Then Drops On Latest Obesity / MASH Data - Why I'm Still BullishSeeking Alpha • 12/05/24
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?The Motley Fool • 12/03/24
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses MomentumBenzinga • 11/29/24
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No TomorrowThe Motley Fool • 11/28/24
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street AnalystThe Motley Fool • 11/25/24
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?Zacks Investment Research • 11/22/24
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheersMarket Watch • 11/20/24
VKTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Viking Therapeutics, Inc.Accesswire • 11/20/24
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024PRNewsWire • 11/19/24
Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTXAccesswire • 11/19/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Viking Therapeutics, Inc. (VKTX) Regarding Potential Securities Fraud AllegationsAccesswire • 11/18/24
ATTENTION VKTX SHAREHOLDERS: Investors who lost money on Viking Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire • 11/17/24